RESPIRERX PHARMACEUTICALS INC.

GLEN ROCK, NJ · Biotech · Public

KRM-II-81, a novel GABA receptor potentiator molecule for epilepsy treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · respirerx.com

Sector: Biotech
Headquarters: GLEN ROCK, NJ
Latest Form D: $2M offered, Aug 2020
Total capital: $16.1M

Federal grants: $1.5M; 1 award · 2025; Rank in peer group#328 of 514
Private capital raised: $14.5M; 14 Form D · last Aug 2020; 75 months since last filing
Federal contracts: $149K; 1 award · Health and Human S; Rank in Biotech#309 of 4373
Granted patents: 0; 3 pending

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase II · Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy$1.5M
Aug 2020Offering registeredForm D · SEC · 14th filing$2M
Aug 2020Private capital raisedForm D · SEC · 13th filing$193K
Sep 2018Private capital raisedForm D · SEC · 12th filing$251K
Sep 2017Private capital raisedForm D · SEC · 11th filing$75K
Mar 2017Private capital raisedForm D · SEC · 10th filing$50K
Jan 2017Private capital raisedForm D · SEC · 9th filing$185K
Jan 2016Private capital raisedForm D · SEC · 8th filing$100K
Sep 2015Private capital raisedForm D · SEC · 7th filing$721K
Nov 2014Private capital raisedForm D · SEC · 6th filing$239K
Apr 2014Private capital raisedForm D · SEC · 5th filing$753K
Aug 2012Private capital raisedForm D · SEC · 4th filing$3.8M
Oct 2011Private capital raisedForm D · SEC · 3rd filing$675K
Jan 2010Private capital raisedForm D · SEC · 2nd filing$1.5M
Aug 2009Private capital raisedForm D · SEC · 1st filing$5.9M

Show 1 earlier federal award

Sep 2014Federal contractHealth and Human S · Igf::ot::igf : Novel Treatment For Drug-induced Respiratory Depression. September 18, 2014 - March 17, 2015. N43DA-14-2239.$149K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Arnold S. LippaExecutive Officer, DirectorNamed in SEC Form D filings
James S. ManusoExecutive Officer, DirectorNamed in SEC Form D filings
James E. SapirsteinDirectorNamed in SEC Form D filings
Jeff E. MargolisExecutive Officer, DirectorNamed in SEC Form D filings
Kathryn E. MacFarlaneDirectorNamed in SEC Form D filings
Richard E. PurcellExecutive OfficerNamed in SEC Form D filings

Show all 8 people

Robert N. WeingartenExecutive Officer, DirectorNamed in SEC Form D filings
Timothy E. JonesExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 3

Oct 23, 2025PendingLipid Nanoparticle Compositions and Methods For Formulating Insoluble DrugsUSPTOApplication 18849500
PendingLipid Nanoparticle Compositions And Methods For Formulating Insoluble DrugsUSPTOApplication PCTUS2023015875
PendingCompositions And Methods For Treating Attention Deficit DisordersUSPTOApplication PCTUS2017024188

ALPHATHERASimilar federal contract value in Biotech · $150K in contracts
CYANVAC LLCSimilar federal contract value in Biotech · $150K in contracts
EVAS THERAPEUTICS LLCSimilar federal contract value in Biotech · $150K in contracts
PROTEIN METRICS INCSimilar federal contract value in Biotech · $147K in contracts
DRVISION TECHNOLOGIES LLCSimilar federal contract value in Biotech · $144K in contracts
28bio, Inc.Similar federal contract value in Biotech · $143K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.